Tradestie Institutional Equity Comparison Engine

TAK vs ELAN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical while ELAN counters with relative strength in Options & Structure. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus ELAN at 20.8x Forward P/E and 7.7% operating margin (+11.3% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against ELAN sits in CONSOLIDATION (1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
TAK 12.7x vs ELAN 20.8x Fwd P/E
Growth & Margin Winner TAK
Op Margin 16.6% vs 7.7% ยท YoY +6.7% vs +11.3%
Momentum & Technical Winner TAK
1Y +51.8% vs +19.9% ยท 52W Pos 97% vs 81%
Options & Structure Winner ELAN
UNCLASSIFIED (5th %ile IV) vs CONSOLIDATION (1st %ile IV)
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
ELAN NYSE
Elanco Animal Health Incorporated Common Stock
Pharmaceutical Preparations
$26.36
-1.59% 1D
Market Cap $13.2B
1M Return +11.91%
1Y Return +19.85%
Forward P/E 20.8x
Unified AI Score
35.7 / 100 SELL
Tech 50.0 Fund 37.0 Flow 71.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TAK +51.79% ELAN +19.85% Spread: +31.94 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TAK TTM Op. Margin: 16.6% ELAN TTM Op. Margin: 7.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs ELAN. Trailing 12-month operating profitability (TAK 16.6% vs ELAN 7.7%) and valuation multiples (TAK 12.7x vs ELAN 20.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TAK (8) vs ELAN (2)
Institutional Metric TAK ELAN Criterion Row Winner
Market Capitalization Scale $67.5B $13.2B Larger Scale TAK
Trailing P/E Ratio Valuation N/M 19.6x Lower Multiple ELAN
Forward P/E Ratio Valuation 12.7x 20.8x Lower Multiple TAK
Revenue Growth (YoY) Growth +6.7% +11.3% Higher Growth ELAN
Operating Margin (TTM) Profitability 16.6% 7.7% Higher Margin TAK
Net Profit Margin Profitability 0.9% -2.9% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency 0.6% -2.2% Higher ROE TAK
52-Week Range Position Momentum 97% ($14โ€“$22) 81% ($19โ€“$28) Stronger Trend TAK
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 22% Vol 1.27ฮฒ ยท 49% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 47.7 / 100 (HOLD) 35.7 / 100 (SELL) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TAK vs ELAN Buy Guide
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ELAN CONSOLIDATION
76d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live ELAN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TAK nor ELAN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.